Wilbanks Smith & Thomas Asset Management LLC cut its stake in Zoetis Inc (NYSE:ZTS) by 26.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,558 shares of the company’s stock after selling 1,599 shares during the quarter. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Zoetis were worth $328,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in ZTS. Dynamic Technology Lab Private Ltd grew its position in Zoetis by 7.3% during the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after buying an additional 401 shares during the period. Daiwa Securities Group Inc. grew its position in Zoetis by 4.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 16,828 shares of the company’s stock valued at $1,212,000 after buying an additional 697 shares during the period. Sandy Spring Bank grew its position in Zoetis by 2.3% during the fourth quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after buying an additional 708 shares during the period. Wendell David Associates Inc. grew its position in Zoetis by 8.4% during the fourth quarter. Wendell David Associates Inc. now owns 10,300 shares of the company’s stock valued at $742,000 after buying an additional 800 shares during the period. Finally, Bath Savings Trust Co grew its position in Zoetis by 18.7% during the third quarter. Bath Savings Trust Co now owns 5,308 shares of the company’s stock valued at $338,000 after buying an additional 835 shares during the period. Hedge funds and other institutional investors own 93.72% of the company’s stock.
Several analysts recently issued reports on ZTS shares. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price for the company. in a research report on Saturday, January 13th. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price for the company in a research report on Wednesday, November 29th. Jefferies Group reiterated a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. Craig Hallum reiterated a “buy” rating and issued a $85.00 price target (up from $77.00) on shares of Zoetis in a research report on Tuesday, January 2nd. Finally, BidaskClub upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $73.72.
Shares of Zoetis Inc (ZTS) opened at $73.00 on Wednesday. The stock has a market cap of $35,664.63, a price-to-earnings ratio of 38.55, a P/E/G ratio of 1.61 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis Inc has a 12 month low of $52.00 and a 12 month high of $80.13.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be paid a dividend of $0.126 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.69%. Zoetis’s dividend payout ratio is presently 26.32%.
ILLEGAL ACTIVITY NOTICE: “Zoetis Inc (ZTS) Shares Sold by Wilbanks Smith & Thomas Asset Management LLC” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/14/zoetis-inc-zts-shares-sold-by-wilbanks-smith-thomas-asset-management-llc.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.